IHS Chemical Week

EnviroTech :: Biotech

Teva to Acquire Ratiopharm for $4.9 Billion

10:46 PM MDT | March 18, 2010 | Deepti Ramesh

Teva Pharmaceutical Industries (Petah Tikva, Israel), the leading generics pharmaceutical company in the world, says it has entered into a definitive agreement to acquire Ratiopharm (Ulm, Germany), the second largest generics producer in Germany and the sixth largest generics drug company worldwide, for an enterprise value of €3.62 billion ($4.9 billion). Teva expects to complete the acquisition by the end of 2010. The acquisition will position Teva as the leading generics company in Europe, Teva says. Ratiopharm had sales of about €1.6 billion ($2.2...

This information is only available to Chemical Week subscribers.


Forgot your user ID or password?
Click here to have it sent to you.

Risk Free Trial

Email Address

First Name

Last Name

Click here to register and get your RISK-FREE access to chemweek.com

Not an IHS Chemical Week
24/7 member yet?

Here's why you should be:

  • Searchable online archive access of the last 2 years of Chemical Week.
  • Print or digital magazine subscription
  • Price and market change alerts
  • Economic data and statistics
  • Buyers' Guides
  • Webcasts | whitepapers




contact us | about us | customer care | privacy policy | sitemap | advertise

ihsCopyright © 2015 IHS, Inc. All rights reserved. Reproduction in whole or in part without permission is prohibited.

North Asia Russia Southeast Asia China India/Pakistan Middle East Eastern Europe Western Europe Central America Canada USA Australia/New Zealand South America Africa